SecBot SecBot

VALN

Valneva SE
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. I0· CIK 0001836564 Biotech & Drug Discovery
$5.65 −0.01 (−0.18%)
Nov 16 4:00 PM ET · prev $5.66
Market cap
$546.5M
Small cap
Median target
$13.00
+130% · range $5.10–18.00
1 year
−36.4%
from $8.89 · Nov 17
30 days
+2.5%
from $5.51
52-week range
$4.78–11.99
−53% from high · low Jul 23
Avg volume 20D
18.8K
Oct 21 spike 137.3K
Short interest
48.0K
≈0.1% of shares · −75.0%
Days to cover
2.0
at average volume
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read MIXED 4 reports · 90 days
Balance 0 bearish · 0 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 3/4

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

  • Oct 30 ▲ Short interest falls 75.0% to 48.0K

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q3 2026: 2 added (0 new), 1 trimmed or exited.

  • Short sellersCOVERING

    Short interest −75.0% to 48.0K shares. 2.0 days to cover, ≈0.1% of shares.

  • TrendDOWNTREND

    5% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
MORGAN STANLEYTRIM27,318$169.0K
BNP PARIBAS FINANCIAL MARKETSDOUBLED8,183$50.6K
OSAIC HOLDINGS, INC.DOUBLED967$6.0K
UBS Group AGDOUBLED4,525$23.7K
BNP PARIBAS FINANCIAL MARKETSDOUBLED559$2.9K
OSAIC HOLDINGS, INC.ADD90$471.00
WELLS FARGO & COMPANY/MNTRIM78,029$487.7K
UBS Group AGDOUBLED782$4.9K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Sep 2025
12-month targets · 4 analysts

Price is inside the target range. Median implies +130%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Sep 8, 2025Guggenheim
MAINTAIN
MAINTAINBuy
Aug 25, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
May 8, 2025Guggenheim
MAINTAIN
MAINTAINBuy
Apr 15, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Apr 9, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Apr 2, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q$0.07$0.07–$0.07+275.0%$45.4M
Current FY🔒 Fresh data, subscribers only
Next FY$1.19$1.19–$1.19+14.4%$283.3M
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

Short side

FINRA· Oct 30, 2026
47,986
shares short
-75.0%
vs prior settlement
2.0
days to cover
≈0.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.

SecBot reports

9 filings · 0 bullish · 0 bearish · 9 neutral
All VALN filing & press-release reports (9)